Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Dianthus Therapeutics (DNTH) Shares Outstanding (Diluted Average): 2022-2025

Historic Shares Outstanding (Diluted Average) for Dianthus Therapeutics (DNTH) over the last 4 years, with Sep 2025 value amounting to $37.8 million.

  • Dianthus Therapeutics' Shares Outstanding (Diluted Average) rose 10.39% to $37.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.8 million, marking a year-over-year increase of 10.39%. This contributed to the annual value of $33.3 million for FY2024, which is 546.44% up from last year.
  • Dianthus Therapeutics' Shares Outstanding (Diluted Average) amounted to $37.8 million in Q3 2025, which was up 5.50% from $35.8 million recorded in Q2 2025.
  • Over the past 5 years, Dianthus Therapeutics' Shares Outstanding (Diluted Average) peaked at $58.8 million during Q2 2022, and registered a low of $874,234 during Q4 2022.
  • Moreover, its 3-year median value for Shares Outstanding (Diluted Average) was $33.3 million (2024), whereas its average is $22.5 million.
  • In the last 5 years, Dianthus Therapeutics' Shares Outstanding (Diluted Average) crashed by 98.51% in 2023 and then spiked by 3,812.11% in 2024.
  • Quarterly analysis of 4 years shows Dianthus Therapeutics' Shares Outstanding (Diluted Average) stood at $874,234 in 2022, then skyrocketed by 489.48% to $5.2 million in 2023, then surged by 546.44% to $33.3 million in 2024, then rose by 10.39% to $37.8 million in 2025.
  • Its last three reported values are $37.8 million in Q3 2025, $35.8 million for Q2 2025, and $35.8 million during Q1 2025.